Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus Cetuximab in Recurrent NSCLC
NCT00216203Phase 2Completed
- Start
- May 2005
- Primary completion
- Dec 2008
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, cetuximab in non-small cell lung cancer (NSCLC). Started May 2005; status: completed.
02
Drugs
pemetrexedcetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00216203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216203.